Evidence map›Paper›PMID 33609494›Full record

ArticleBiophysical journal2021

A potential interaction between the SARS-CoV-2 spike protein and nicotinic acetylcholine receptors.

A Sofia F Oliveira, Amaurys Avila Ibarra, Isabel Bermudez, Lorenzo Casalino, Zied Gaieb, Deborah K Shoemark, Timothy Gallagher, Richard B Sessions, Rommie E Amaro, Adrian J Mulholland

Open access · bronzeAbstract read
In one paragraph

Article in Biophysical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 78 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. An experimental test of the nicotinic hypothesis of COVID-19.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

A Sofia F OliveiraCentre for Computational Chemistry, School of Chemistry, University of Bristol, Bristol, United Kingdom; Bristol Synthetic Biology Centre, BrisSynBio, Bristol, United Kingdom.
Amaurys Avila IbarraResearch Software Engineering, Advanced Computing Research Centre, University of Bristol, Bristol, United Kingdom.
Isabel BermudezDepartment of Biological and Medical Sciences, Oxford Brookes University, Oxford, United Kingdom.
Lorenzo CasalinoDepartment of Chemistry and Biochemistry, University of California San Diego, La Jolla, California.
Zied GaiebDepartment of Chemistry and Biochemistry, University of California San Diego, La Jolla, California.
Deborah K ShoemarkSchool of Biochemistry, University of Bristol, Bristol, United Kingdom; Bristol Synthetic Biology Centre, BrisSynBio, Bristol, United Kingdom.
Timothy GallagherCentre for Computational Chemistry, School of Chemistry, University of Bristol, Bristol, United Kingdom.
Richard B SessionsSchool of Biochemistry, University of Bristol, Bristol, United Kingdom.
Rommie E AmaroDepartment of Chemistry and Biochemistry, University of California San Diego, La Jolla, California.
Adrian J MulhollandCentre for Computational Chemistry, School of Chemistry, University of Bristol, Bristol, United Kingdom. Electronic address: adrian.mulholland@bristol.ac.uk.
University of Bristol · GBUniversity of California San Diego · USOxford Brookes University · GB

Funding

A MULTISCALE APPROACH TO TARGET THE ACHILLES HEEL OF P53 CANCER MUTANTS (Equipment Supplement)R01GM132826 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI AMARO, ROMMIE E · 2019 to 2022
$1.3M
Biotechnology and Biological Sciences Research Council BB/L01386X/1NIGMS NIH HHS R01 GM132826
6 · The paper itself

Abstract

Changeux et al. (Changeux et al. C. R. Biol. 343:33-39.) recently suggested that the SARS-CoV-2 spike protein may interact with nicotinic acetylcholine receptors (nAChRs) and that such interactions may be involved in pathology and infectivity. This hypothesis is based on the fact that the SARS-CoV-2 spike protein contains a sequence motif similar to known nAChR antagonists. Here, we use molecular simulations of validated atomically detailed structures of nAChRs and of the spike to investigate the possible binding of the Y674-R685 region of the spike to nAChRs. We examine the binding of the Y674-R685 loop to three nAChRs, namely the human α4β2 and α7 subtypes and the muscle-like αβγδ receptor from Tetronarce californica. Our results predict that Y674-R685 has affinity for nAChRs. The region of the spike responsible for binding contains a PRRA motif, a four-residue insertion not found in other SARS-like coronaviruses. The conformational behavior of the bound Y674-R685 is highly dependent on the receptor subtype; it adopts extended conformations in the α4β2 and α7 complexes but is more compact when bound to the muscle-like receptor. In the α4β2 and αβγδ complexes, the interaction of Y674-R685 with the receptors forces the loop C region to adopt an open conformation, similar to other known nAChR antagonists. In contrast, in the α7 complex, Y674-R685 penetrates deeply into the binding pocket in which it forms interactions with the residues lining the aromatic box, namely with TrpB, TyrC1, and TyrC2. Estimates of binding energy suggest that Y674-R685 forms stable complexes with all three nAChR subtypes. Analyses of simulations of the glycosylated spike show that the Y674-R685 region is accessible for binding. We suggest a potential binding orientation of the spike protein with nAChRs, in which they are in a nonparallel arrangement to one another.

Indexed as

GlycosylationHumansMolecular Dynamics SimulationPeptidesProtein BindingReceptors, NicotinicSpike Glycoprotein, CoronavirusThermodynamicsPeptidesReceptors, NicotinicSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID33609494
PMCPMC7889469
OpenAlexW3128519700

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.